RxDoctor Payments DataLook up a doctor →

Joel Shebowich, MD

Internal Medicine · Centennial, CONPI 1366468902

Payments from drug & device makers

$32,390in general payments, 2019–2025

Across 765 payments — averaging $42.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$17K
  • National Marrow Donor Program$3K
  • AbbVie$2K
  • AstraZeneca$1K
  • Amgen$1K
  • Novo Nordisk$985
  • plus $7K from 46 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$13,94543%
  • Travel & lodging$4,84815%
  • Food & beverage$13,41641%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,390 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$78,529
Medicare patients
237
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$128,012
MounjaroTirzepatide62$101,139
JardianceEmpagliflozin55$68,615
EliquisApixaban63$58,814
TrulicityDulaglutide21$47,680
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$35,624
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$29,526
FarxigaDapagliflozin Propanediol14$20,843
Synjardy XrEmpagliflozin/Metformin Hcl16$20,697
Soliqua 100-33Insulin Glargine/Lixisenatide11$16,064
Tresiba Flextouch U-100Insulin Degludec25$16,062
SynjardyEmpagliflozin/Metformin Hcl17$15,582
QuliptaAtogepant11$12,431
ShingrixVaricella-Zoster Ge/As01b/Pf54$11,969
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$835$148,82083 claims
Novo NordiskOzempic$985$128,01281 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$507$104,89488 claims
PfizerEliquis$613$58,81463 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,425$56,46651 claims
GSKTrelegy Ellipta, Shingrix$357$41,49575 claims
AbbVieQulipta, Synthroid$2,128$16,49655 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$846$16,06411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Centennial

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →